Review



human mesenchymal stem cell functional identification kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    R&D Systems human mesenchymal stem cell functional identification kit
    Effect of MTX, PSL, adalimumab, and tocilizumab on MSC differentiation into adipocytes. (A) Typical imaging screening panel for quantification of mFABP4 expression. MSCs were seeded on 96-well plates, and 32 fields were captured in each well using a high-throughput image quantitation system. One of 32 fields is shown. (B, C) The titration curve of mFABP4 expression in MSCs treated with (B) (MTX or PSL, and (C) adalimumab or tocilizumab. The average change of fluorescent intensity was obtained from 96 images for each concentration. Results are presented as mean ± SEM. (D) Typical images of lipid droplets analysis in antirheumatic drug-treated MSCs. Following Oil Red O staining, lipid droplets present as red-stained areas. (E, F) Changes in positive area of lipid droplet in MSCs treated with (E) MTX or PSL, and (F) adalimumab or tocilizumab. The red-stained area was calibrated by the number of nuclei. Results are presented as mean ± SEM. mFABP4, mouse fatty acid binding protein; MSC, <t>mesenchymal</t> stem cell; MTX, methotrexate; PSL, prednisolone; SEM, standard error of the mean.
    Human Mesenchymal Stem Cell Functional Identification Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 132 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+functional+screen+elisa+kit/Human+Mesenchymal+Stem+Cell+Functional+Identification+Kit/pmc07348038-33-6-13
    Average 99 stars, based on 132 article reviews
    human mesenchymal stem cell functional identification kit - by Bioz Stars, 2026-09
    99/100 stars

    Images

    1) Product Images from "Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells"

    Article Title: Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2020.01004

    Effect of MTX, PSL, adalimumab, and tocilizumab on MSC differentiation into adipocytes. (A) Typical imaging screening panel for quantification of mFABP4 expression. MSCs were seeded on 96-well plates, and 32 fields were captured in each well using a high-throughput image quantitation system. One of 32 fields is shown. (B, C) The titration curve of mFABP4 expression in MSCs treated with (B) (MTX or PSL, and (C) adalimumab or tocilizumab. The average change of fluorescent intensity was obtained from 96 images for each concentration. Results are presented as mean ± SEM. (D) Typical images of lipid droplets analysis in antirheumatic drug-treated MSCs. Following Oil Red O staining, lipid droplets present as red-stained areas. (E, F) Changes in positive area of lipid droplet in MSCs treated with (E) MTX or PSL, and (F) adalimumab or tocilizumab. The red-stained area was calibrated by the number of nuclei. Results are presented as mean ± SEM. mFABP4, mouse fatty acid binding protein; MSC, mesenchymal stem cell; MTX, methotrexate; PSL, prednisolone; SEM, standard error of the mean.
    Figure Legend Snippet: Effect of MTX, PSL, adalimumab, and tocilizumab on MSC differentiation into adipocytes. (A) Typical imaging screening panel for quantification of mFABP4 expression. MSCs were seeded on 96-well plates, and 32 fields were captured in each well using a high-throughput image quantitation system. One of 32 fields is shown. (B, C) The titration curve of mFABP4 expression in MSCs treated with (B) (MTX or PSL, and (C) adalimumab or tocilizumab. The average change of fluorescent intensity was obtained from 96 images for each concentration. Results are presented as mean ± SEM. (D) Typical images of lipid droplets analysis in antirheumatic drug-treated MSCs. Following Oil Red O staining, lipid droplets present as red-stained areas. (E, F) Changes in positive area of lipid droplet in MSCs treated with (E) MTX or PSL, and (F) adalimumab or tocilizumab. The red-stained area was calibrated by the number of nuclei. Results are presented as mean ± SEM. mFABP4, mouse fatty acid binding protein; MSC, mesenchymal stem cell; MTX, methotrexate; PSL, prednisolone; SEM, standard error of the mean.

    Techniques Used: Imaging, Expressing, High Throughput Screening Assay, Quantitation Assay, Titration, Concentration Assay, Staining, Binding Assay

    Osteogenic differentiation potencies of antirheumatic drug-treated MSCs. (A) Typical imaging screening panel for quantification of osteocalcin expression. One of 32 screening panels is shown. (B , C) The titration curve of osteocalcin expression in MSCs treated with (B) MTX or PSL, and (C) adalimumab or tocilizumab. Average change of fluorescent intensity was obtained from 96 images for each concentration. Results are presented as mean ± SEM. (D) Typical images of ALP-activity analysis in antirheumatic drug-treated MSCs. Positive areas present as purple-stained areas (200×; scale bar: 40 μm). (E , F) Changes of relative positive area of ALP-activity assay in MSCs treated with (E) MTX or PSL, and (F) adalimumab or tocilizumab. The purple-stained area was segmented from the background and the change of relative area was quantified. More than four fields per section and an average of five sections for each concentration were used for semiquantitative analysis. Results are presented as mean ± SEM. ALP, alkaline phosphatase; MSC, mesenchymal stem cell; MTX, methotrexate; PSL, prednisolone; SEM, standard error of the mean.
    Figure Legend Snippet: Osteogenic differentiation potencies of antirheumatic drug-treated MSCs. (A) Typical imaging screening panel for quantification of osteocalcin expression. One of 32 screening panels is shown. (B , C) The titration curve of osteocalcin expression in MSCs treated with (B) MTX or PSL, and (C) adalimumab or tocilizumab. Average change of fluorescent intensity was obtained from 96 images for each concentration. Results are presented as mean ± SEM. (D) Typical images of ALP-activity analysis in antirheumatic drug-treated MSCs. Positive areas present as purple-stained areas (200×; scale bar: 40 μm). (E , F) Changes of relative positive area of ALP-activity assay in MSCs treated with (E) MTX or PSL, and (F) adalimumab or tocilizumab. The purple-stained area was segmented from the background and the change of relative area was quantified. More than four fields per section and an average of five sections for each concentration were used for semiquantitative analysis. Results are presented as mean ± SEM. ALP, alkaline phosphatase; MSC, mesenchymal stem cell; MTX, methotrexate; PSL, prednisolone; SEM, standard error of the mean.

    Techniques Used: Imaging, Expressing, Titration, Concentration Assay, Activity Assay, Staining, ALP Activity Assay

    In vitro chondrogenic assessment of antirheumatic agent-treated MSC-spheroids. (A) Micromass formation by antirheumatic agent-treated spheroids after 28 days of induction culture. (B) Typical images of aggrecan and CD44 expression in MSC spheroids. Fixed micromasses were embedded and sectioned on a cryotome. Expression of aggrecan (green) and CD44 (red) were observed using immunohistochemical staining (200×; scale bar: 40 μm). (C–F) Quantification of volume of micromass formed by chondrospheroids treated with (C) MTX, (D) PSL, (E) adalimumab, and (F) tocilizumab. MRI imaging of micromass was acquired under a three-dimensional T2-weighted flash sequence protocol; coronal and sagittal images were collected and reconstructed to obtain the volume of chondrospheroids. Results are expressed as the mean ± standard deviation (SD) (n=5). MSC, mesenchymal stem cell; MRI, magnetic resonance imaging; MTX, methotrexate; PSL, prednisolone.
    Figure Legend Snippet: In vitro chondrogenic assessment of antirheumatic agent-treated MSC-spheroids. (A) Micromass formation by antirheumatic agent-treated spheroids after 28 days of induction culture. (B) Typical images of aggrecan and CD44 expression in MSC spheroids. Fixed micromasses were embedded and sectioned on a cryotome. Expression of aggrecan (green) and CD44 (red) were observed using immunohistochemical staining (200×; scale bar: 40 μm). (C–F) Quantification of volume of micromass formed by chondrospheroids treated with (C) MTX, (D) PSL, (E) adalimumab, and (F) tocilizumab. MRI imaging of micromass was acquired under a three-dimensional T2-weighted flash sequence protocol; coronal and sagittal images were collected and reconstructed to obtain the volume of chondrospheroids. Results are expressed as the mean ± standard deviation (SD) (n=5). MSC, mesenchymal stem cell; MRI, magnetic resonance imaging; MTX, methotrexate; PSL, prednisolone.

    Techniques Used: In Vitro, Expressing, Immunohistochemical staining, Staining, Imaging, Sequencing, Standard Deviation, Magnetic Resonance Imaging

    Establishment an in vivo chondrogenic drug-screening system. (A) Cartilaginous mass formation in chondrospheroid-engrafted mice. Chondrospheroids with and without scaffold were implanted to NOD/SCID mice preengrafted with healthy-donor derived PBMCs. Four weeks later, cartilaginous particles had formed. (B) Typical images of aggrecan and CD44 expression in MSC spheroids before engrafting and 4 weeks after chondrospheroid transplantation. Expression of aggrecan (green) and CD44 (red) were observed using immunohistochemical staining (200×; scale bar: 40 μm). (C) Cartilage regenerative capability of chondrospheroids. Predifferentiated chondrospheroids were transplanted into a human xenografted RA model. Implanted RA-patient derived synovium, cartilage, and bone were explanted 8 weeks after chondrospheroid transplantation. Hematoxylin and eosin staining was performed on sections; typical images are shown (200×; scale bar: 20 μm; arrow: synovial invasion to cartilage). (D–G) Quantification of volume of cartilaginous particles formed in mice treated with (D) MTX, (E) PSL, (F) adalimumab, or (G) tocilizumab. Antirheumatic agents were continuously subcutaneously infused for 30 days in chondrospheroid-engrafted mice. MRI imaging of explanted micromass was acquired to evaluate the volume of chondrospheroids. Results are described as the median and interquartile range (difference between 25 th and 75 th percentiles) (n=5). MSC, mesenchymal stem cell; MTX, methotrexate; PBMCs, peripheral blood mononuclear cells; PSL, prednisolone.
    Figure Legend Snippet: Establishment an in vivo chondrogenic drug-screening system. (A) Cartilaginous mass formation in chondrospheroid-engrafted mice. Chondrospheroids with and without scaffold were implanted to NOD/SCID mice preengrafted with healthy-donor derived PBMCs. Four weeks later, cartilaginous particles had formed. (B) Typical images of aggrecan and CD44 expression in MSC spheroids before engrafting and 4 weeks after chondrospheroid transplantation. Expression of aggrecan (green) and CD44 (red) were observed using immunohistochemical staining (200×; scale bar: 40 μm). (C) Cartilage regenerative capability of chondrospheroids. Predifferentiated chondrospheroids were transplanted into a human xenografted RA model. Implanted RA-patient derived synovium, cartilage, and bone were explanted 8 weeks after chondrospheroid transplantation. Hematoxylin and eosin staining was performed on sections; typical images are shown (200×; scale bar: 20 μm; arrow: synovial invasion to cartilage). (D–G) Quantification of volume of cartilaginous particles formed in mice treated with (D) MTX, (E) PSL, (F) adalimumab, or (G) tocilizumab. Antirheumatic agents were continuously subcutaneously infused for 30 days in chondrospheroid-engrafted mice. MRI imaging of explanted micromass was acquired to evaluate the volume of chondrospheroids. Results are described as the median and interquartile range (difference between 25 th and 75 th percentiles) (n=5). MSC, mesenchymal stem cell; MTX, methotrexate; PBMCs, peripheral blood mononuclear cells; PSL, prednisolone.

    Techniques Used: In Vivo, Drug discovery, Derivative Assay, Expressing, Transplantation Assay, Immunohistochemical staining, Staining, Imaging

    Related Articles

    In Vitro:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Functional Assay:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Staining:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Expressing:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Cell Culture:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Ubiquitin Proteomics:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Differentiation Assay:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    FACS:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie

    Isolation:

    Article Title: Priming-Dependent Modulation of Secretome in Placenta- and Adipose-Derived Mesenchymal Stromal/Stem Cells: Toward Cell-Free Immunoregenerative Therapies for Osteochondral and Degenerative Joint Diseases.
    Article Snippet: , the multipotent differentiation potential of PDSCs and ASCs was evaluated in vitro. PDSC multipotency was assessed using the Human Mesenchymal Stem Cell Functional Identification Kit (cat. N. SC006, Bio-Techne, USA) as previously described [27]. Briefly, osteogenic and adipogenic differentiation were induced by culturing the cells for 14 days in α-MEM supplemented with 10% FBS (Thermo Fisher Scie



    Similar Products

    total complement functional screen elisa kit  (Eagle Biosciences)
    92
    Eagle Biosciences total complement functional screen elisa kit
    Total Complement Functional Screen Elisa Kit, supplied by Eagle Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+functional+screen+elisa+kit/Total+complement+functional+screen+ELISA/pm37887754-49-11-17
    Average 92 stars, based on 1 article reviews
    total complement functional screen elisa kit - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    complement functional screen elisa kit  (Eagle Biosciences)
    92
    Eagle Biosciences complement functional screen elisa kit
    Complement Functional Screen Elisa Kit, supplied by Eagle Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+functional+screen+elisa+kit/Total+complement+functional+screen+ELISA/pm37887754-49-12-17
    Average 92 stars, based on 1 article reviews
    complement functional screen elisa kit - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier

    Image Search Results